Bedaquiline Efficacy in the Russian Federation: Meta-analysis with a Random Effects Model

The objective: to determine the rate of treatment success in MDR and XDR pulmonary tuberculosis patients when treated with chemotherapy regimens containing bedaquiline based on a meta-analysis using mathematical modeling. Subjects Methods. We searched analyzed published studies conducted from 2014 2022 Russian Federation. A total 41 publications were found, which 15 included since they contained data eligible for analysis. They presented results 1,356 TB patients, 886 (65,3%) had TB, 470 (34,7%) (according definition as 2020). All them received within standard regimen 24–26 weeks. Results. According results, MDR/XDR sputum conversion was achieved 79,6% (95% CI 75,1–83,4) cases, effective observed 82,0% 78,6–84.9) cases. Treatment default noted 8,7% 5,7–13,1) At same time, there is statistically significant relationship ( p <0,01) between proportion comorbidities incomplete treatment. Lethal outcomes recorded 5,8% 3,6–9,2), associated severe course concomitant pathology. Bedaquiline canceled 7,8% 4,0–13,5) When analyzing separately, efficacy differed amounted 89,9% 85,9–92,9) versus 71,9% 66,3–76,8), respectively.